Business · 02/04/2014Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for NOVOTFF-100A SYSTEM Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the NOVOTFF-100A SYSTEM medical device patent extension, as mandated by law, following a submission to the US Department of Commerce's Director of Patents and Trademarks.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →